Osaka University Venture Fund and Nippi Co. invest in Matrixome, a stem-cell venture

The venture will focus on the use of the recombinant laminin 511E8 fragment which was developed by Kyoto University iPS Cell Research members and is now marketed by Nippi, a collagen product company. Matrixome will develop various equipment coated with this laminin derivative for use in cell culture technology.

Nippi news release, February 1, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny